|
CEO:
|
Mr. Tadashi Fujisawa
|
|
(
Former GlaxoSmithKline Marketing Div.;
New Product Div. )
|
|
|
|
Director:
|
Dr. Kazuo Maruyama
|
|
(Professor,
Department of Biopharmaceutics, School of
Pharmaceutical Sciences, Teikyo University)
|
|
|
|
Director:
|
Dr.
Donghyun Kim
|
|
(Former Baxter Non-clinical Division, R&D）
|
|
|
|
Director:
|
Mr.
Nobuyuki Yamagata
|
|
(Former Aventis -Pharma）
|
|
|
|
Director:
|
Mr.
Takeshi Mori
|
|
(Former GlaxoSmithKline）
|
|
|
|
Director:
|
Mr.
Kazushi Okada
|
|
(Former Shiratori Pharmaceuticals, Inc.）
|
|
|
|
|
|
|
Auditor:
|
Dr.
Tadayuki Ibuki
|
|
(Former
ASAHI KASEI Corporation, General Manager)
|
|
Auditor:
|
Mr. Ryoichi Nishizawa
|
|
(Certified
Public Accountant, Licensed Tax Accountant)
|
|
Auditor:
|
Dr.
Yoshiki Suzuki
|
|
(Lecturer,
the Faculty of Pharmaceutical Sciences,
Hoshi University)
|
|
|
|
|
Advisor:
|
Dr. Hironobu
Yanagie
|
|
(Associate Professor,
Research Center for Advanced Science and Technology,
The University of Tokyo)
|
|
|
|
|
